Study Evaluating Efficiency and Tolerance of High-dose Fluconazole Associated With Flucytosine as Induction Therapy for Cryptococcal Meningitis Associated With HIV in Sub-saharan Africa
NCT01715922 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 41
Last updated 2016-07-12
Summary
The aim of the trial is to demonstrate that in a sub-Saharan African setting, the association of:
1. Oral treatment : high dose of fluconazole (1600mg/d) associated with flucytosine (100 mg/kg/j) as induction therapy
2. lumbar punctures to control intracranial pressure
can decrease mortality rate below 35% at 10 weeks.
This is a non-randomized open label pilot study, with standardized management of cryptococcoses meningitis and follow-up in Burundi and Ivory Coast. A total of 41 patients will be enrolled.
Conditions
- Cryptococcal Meningitis
- HIV
Interventions
- DRUG
-
Fluconazole
Induction treatment for 2 weeks: Fluconazole (1600mg/j) Consolidation treatment for 8 weeks: fluconazole (800 mg/j)
- DRUG
-
Flucytosine
Flucytosine (100 mg/kg/j) for 2 weeks
- PROCEDURE
-
lumbar punctures
lumbar punctures to control intracranial pressure
Sponsors & Collaborators
-
CHU Kamenge, BURUNDI
collaborator UNKNOWN -
Hospital Avicenne
collaborator OTHER -
Institut Pasteur
collaborator INDUSTRY -
Hôpital Necker-Enfants Malades
collaborator OTHER -
Institut de Médecine et Epidémiologie Appliquée (IMEA)
collaborator UNKNOWN -
Hôpital de Treichville
collaborator UNKNOWN -
Hôpital Cocody
collaborator UNKNOWN -
ANRS, Emerging Infectious Diseases
lead OTHER_GOV
Principal Investigators
-
Olivier Bouchaud, PhD · Hopital Avicenne, Service des maladies infectieuses, Paris, france
-
Théodore Niyangobo, PhD · CHU Kamenge, Bujumbura, Burundi
-
Amélie Chabrol, MD · Hopital Avicenne, Service des maladies infectieuses, Paris, france
-
Kakou AKA, Professor · CHU Triechville
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2012-05-31
- Primary Completion
- 2015-09-30
- Completion
- 2016-09-30
Countries
- Burundi
- Côte d’Ivoire
Study Locations
More Related Trials
-
An Open, Non-Comparative Study of Intravenous and Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis
NCT00002077 ·Status: COMPLETED ·Phase: NA
-
A Randomized Double Blind Protocol Comparing Amphotericin B With Flucytosine to Amphotericin B Alone Followed by a Comparison of Fluconazole and Itraconazole in the Treatment of Acute Cryptococcal Meningitis
NCT00000639 ·Status: COMPLETED ·Phase: NA
-
Pilot Study of Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis
NCT00002076 ·Status: COMPLETED ·Phase: NA
-
Open, Non-Comparative Study of Fluconazole in Patients With Coccidioidal Meningitis
NCT00002010 ·Status: COMPLETED ·Phase: NA
-
A Comparison of Fluconazole and Amphotericin B in the Treatment of Cryptococcal Meningitis
NCT00002305 ·Status: COMPLETED ·Phase: NA
-
Platform Trial For Cryptococcal Meningitis
NCT06666322 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Optimizing the Dose of Flucytosine for the Treatment of Cryptococcal Meningitis
NCT06414512 ·Status: COMPLETED ·Phase: PHASE2
-
Clinical Effectiveness and Safety of Amphotericin B With Flucytosine-Fluconazole Therapy for Cryptococcal Meningitis
NCT04532463 ·Status: COMPLETED
-
Amphotericin Alone or in Combination With Fluconazole for AIDS-Associated Meningitis
NCT00145249 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Fluconazole in the Prevention of Fungal Infections in HIV-Infected Patients Living in Areas Where Fungal Infections Are Common
NCT00002325 ·Status: COMPLETED ·Phase: NA
-
A Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis
NCT00002068 ·Status: COMPLETED ·Phase: NA
-
Three Induction Treatments on Cryptococcal Meningitis
NCT04072640 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Operational Research for Cryptococcal Antigen Screening
NCT01535469 ·Status: COMPLETED ·Phase: PHASE4
-
Safety Study of Fluconazole in Combination With Flucytosine for the Treatment of Early Cryptococcal Infection
NCT01562132 ·Status: TERMINATED ·Phase: PHASE2
-
Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis
NCT00002075 ·Status: COMPLETED ·Phase: NA
-
Multi-center Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis
NCT00000708 ·Status: COMPLETED ·Phase: NA
-
A Comparison of Fluconazole and Amphotericin B in the Treatment of Fungal Infections
NCT00002277 ·Status: COMPLETED ·Phase: PHASE3
-
Comparison of Fluconazole and Amphotericin B in the Treatment of Brain Infections in Patients With AIDS
NCT00001017 ·Status: COMPLETED ·Phase: PHASE3
-
Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Maintenance Treatment for the Prevention of Relapse of Cryptococcal Meningitis in Patients With Acquired Immunodeficiency Syndrome
NCT00002074 ·Status: COMPLETED ·Phase: NA
-
Vietnam Cryptococcal Retention in Care Study Version 1.0
NCT02334670 ·Status: UNKNOWN
-
Pilot Study to Determine the Feasibility of Fluconazole for Induction Treatment and Suppression of Relapse of Histoplasmosis in Patients With the Acquired Immunodeficiency Syndrome
NCT00000627 ·Status: COMPLETED ·Phase: NA
-
Single Dose Liposomal Amphotericin for Asymptomatic Cryptococcal Antigenemia
NCT03945448 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
The Study Of Fluconazole For Vulvovaginal Candidiasis
NCT01806623 ·Status: COMPLETED ·Phase: PHASE3
-
Phase II Pilot Study of Fluconazole for Histoplasmosis, Blastomycosis, and Sporotrichosis
NCT00004808 ·Status: COMPLETED ·Phase: PHASE2
-
Non-Comparative Study of Fluconazole in Patients With Serious Mycoses and Who Cannot Be Treated With Conventional Antifungal Therapy
NCT00002038 ·Status: COMPLETED ·Phase: NA